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Abstract
Background: Omeprazole is metabolized by the hepatic cytochrome P450 (CYP) 2C19 enzyme
to 5-hydroxyomeprazole. CYP2C19 exhibits genetic polymorphisms responsible for the presence
of poor metabolizers (PMs), intermediate metabolizers (IMs) and extensive metabolizers (EMs).
The defective mutations of the enzyme and their frequencies change between different ethnic
groups; however, the polymorphism of the CYP2C19 gene has not been studied in Colombian
mestizos. The aim of this study was to evaluate the genotype and phenotype status of CYP2C19 in
Colombian mestizos, in order to contribute to the use of appropriate strategies of drug therapy
for this population.
Methods: 189 subjects were genotyped using the multiplex SNaPshot technique and a subgroup
of 44 individuals received 20 mg of omeprazole followed by blood collection at 3 hours to
determine the omeprazole hydroxylation index by HPLC.
Results: 83.6%, 15.3% and 1.1% of the subjects were genotyped as EMs, IMs and PMs, respectively.
The frequencies of the CYP2C29*1 and CYP2C19*2 alleles were 91.3% and 8.7% respectively
whereas the *3, *4, *5, *6 and *8 alleles were not found. No discrepancies were found between
the genotype and phenotype of CYP2C19.
Conclusion: The frequency of poor metabolizers (1.1%) in the Colombian mestizos included in
this study is similar to that in Bolivian mestizos (1%) but lower than in Mexican-Americans (3.2%),
West Mexicans (6%), Caucasians (5%) and African Americans (5.4%). The results of this study will
be useful for drug dosage recommendations in Colombian mestizos.
Background
The CYP2C19 isoenzyme, a member of the superfamily of
xenobiotic enzymes of cytochrome P-450, is responsible
for the metabolism of several therapeutically important
drugs, such as proton-pump inhibitors (omeprazole, lan-
soprazole, pantoprazole), antidepressants (citalopram,
imipramine), benzodiazepines (diazepam, fluni-
trazepam), propranolol and proguanil [1-3].
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The CYP2C19 gene polymorphism divides populations in
three phenotypic subgroups: extensive metabolizers
(EMs), intermediate metabolizers (IMs), and poor metab-
olizers (PMs). The enzymatic deficiency is inherited as an
autosomal recessive trait [4].
The frequencies and types of alleles vary between ethnic
groups. Thus, 13 to 23% of Orientals are PMs and the
CYP2C19*2 and *3 alleles account for 99% of them in
this ethnic group [5], whereas in Caucasians, with a per-
centage of PMs near to 5% of the population, only the *2
allele is common although other variants have been
described [6-9]. In Black population some new mutations
(*9, *10, *12) have been reported and the frequency of
PMs individuals is 5.4% [10,11]. The clinical conse-
quences of the CYP2C19 gene polymorphisms have not
been fully understand but can be illustrated with the case
of proton-pump inhibitors. The EMs metabolizes these
drugs at a speed that requires doses up to four times
greater than PMs to reach similar serum concentrations
and effects [12,13].
Several studies carried out in different ethnic groups have
shown that the efficacy of proton-pump inhibitors is
related to the CYP2C19 genotype, explaining the differ-
ences in terms of therapeutic efficacy observed between
EMs and PMs individuals [14-19]. Nevertheless, the resist-
ance of H. pylori to antimicrobial and others non-genetic
factors such as age, liver disease and enzymatic inhibition
or induction by drugs are also important causes of thera-
peutic failure [3,20,21].
Although the genotype-phenotype correlation for
CYP2C19 using omeprazole as "probe drug" has been
widely studied, there are no data regarding South Ameri-
can Mestizos [22,23]. Therefore, the aim of this study was
to evaluate the genotype and phenotype status of
CYP2C19 in Colombian mestizos, in order to contribute
to the use of appropriate strategies of drug therapy for this
population. Colombian population is divided ethnically
into four main groups: the Mestizo (56%), White
(30.1%), Black (10.5%) and Amerindian (3.4%) people.
The Colombian mestizo population is an admixture
between Amerindian, Hispanic and African descent [24].
Methods
Subjects
Healthy unrelated Colombian mestizos (n = 189) partici-
pated in the study. None of the volunteers included in the
phenotyping test (n = 44) had a history of allergy to ome-
prazole or other drugs, alcohol abuse, drug addiction or a
smoking habit of more than 15 cigarettes/day. The partic-
ipants were not allowed to take any medication during the
previous week before and during the study [25]. The
experimental protocol was approved by the Ethics Com-
mittee of Universidad Tecnológica de Pereira, Colombia.
Written informed consent was obtained from all partici-
pating subjects.
CYP2C19 genotyping
A multiplex primer-extension assay that simultaneously
detects the six CYP2C19 alleles using the ABI Prism®
SNaPshot™ ddNTP Primer-Extension Assay was used [26].
Buccal swabs were obtained from experimental subjects
and the material was deposited onto FTA blood cards,
dried at room temperature and stored for DNA extraction
as reported [27]. The DNA was used to amplify five frag-
ments of the CYP2C19 gene corresponding to exons 1
(410 bp), 2–3 (719 bp), 4 (310 bp), 5 (410 bp) and 9
(529 bp); which include the six Single Nucleotide Poly-
morphisms (SNPs) studied. Amplification was carried out
on a DNA thermal cycler PBX2 (Thermo Electron Corpo-
ration), according to previously described techniques
[28]. PCR products were electrophoresed in 2% agarose
gels and the bands purified using the GFX purification kit
(Amersham Pharmacia Biotech). The amplification prod-
ucts were used as templates for the multiplex reactions in
order to detect the wild-type allele CYP2C19*1 and the
*2, *3, *4, *5, *6 and *8 mutations.
The minisequencing was based on the method proposed
by Bender et al [26], with detection primers present in the
reaction at a concentration of 1.5 pmoles. The amplifica-
tion products were injected onto the DNA ABI prism 3100
Avant Genetic Analyzer ant the results were analyzed
using the GeneMapper Analysis Software (PE Applied Bio-
systems).
CYP2C19 phenotyping
The omeprazole hydroxylation index (HI) was deter-
mined in 44 subjects previously genotyped. After an over-
night fast, each subject took 20 mg omeprazole
(Tecnoquímicas, Cali, Colombia) orally. Then, 3 h after
ingestion of the drug, 5 ml of venous blood was collected
from an antecubital vein into tubes with anticoagulant.
Plasma was separated after centrifugation and stored fro-
zen at -20°C until analysis. The concentration of omepra-
zole and 5-hydroxy omeprazole in plasma was measured
by HPLC as described by Gonzalez et al [29], with some
modifications. Omeprazole and 5-hydroxy omeprazole
were purchased from Sigma-Aldrich Co (St. Louis, USA)
and SynFine Research Inc. (Ontario, Canada), respec-
tively. To avoid recovery problems, standards were pre-
pared by spiking blank plasma with omeprazole and 5-
hydroxy omeprazole to get concentrations of 0.1, 0.25,
1.0, 3.0 and 5.0 µg/mL and processed by solid phase
extraction (SPE) in the same way as samples. Standards
and samples (2 mL) were submitted to SPE using 500 mg
RP-18 cartridges (Merck) previously activated with AcCN
(3 mL), followed by three portions of 3 mL of phosphateBMC Clinical Pharmacology 2007, 7:6 http://www.biomedcentral.com/1472-6904/7/6
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buffer (0.05 M, pH 7.2). After sample application the car-
tridge was washed sequentially by three 0.5 mL portions
of phosphate buffer and a 0.5 mL portion of phosphate
buffer-AcCN (80:20), drying after each washing. Analytes
were eluted with phosphate buffer-AcCN (10:90). HPLC
analysis was carried out in a Jasco HPLC 2000 plus Series
System equipped with a PU-2089 Plus Quaternary Gradi-
ent Pump, an AS-2059 Plus Intelligent Autosampler, a
CO-2065 Plus Column Oven, a MD-2015 Plus Intelligent
Diode Array Detector, and a LC Net II/ADC, controlled by
EZChrom Elite Software version 3.16. Each standard and
sample were injected (25 µL) into an Ultra Aqueous RP-
18 Restek analytical column (3 µm particle size, 100 × 3.2
mm I.D.), eluting in isocratic mode with phosphate
buffer-AcCN (70:30) as mobile phase at 0.5 mL/min flow
rate. Calibration curve and quantification were performed
at 298 nm by external standard, with linear fit showing a
coefficient of determination (r2) of 0.9993 for omepra-
zole and 0.9992 for 5-hydroxyomeprazole in the range
from 0.1 to 5 µg/mL. Omeprazole and its metabolite 5-
hydroxyomeprazole eluted at 9.80 min and 3.67 min,
respectively. Detection limits were 0.026 µg/mL for ome-
prazole and 0.01 µg/mL for 5-hydroxyomeprazole. Intra-
day coefficients of variation for omeprazole and 5-
hydroxyomeprazole were 5% and 4%, respectively. Indi-
viduals with a metabolic ratio (MR) ≥ 0.63 were pheno-
typed as PMs.
Statistical analysis
Allelic frequencies were calculated according to the
number of alleles observed and the number of chromo-
somes examined. The Hardy-Weinberg equilibrium was
established using the Chi-square test. The MR was calcu-
lated as log10  (omeprazole/hydroxyomeprazole)
[21,29,30]. The normality of the MR distribution was
evaluated by the D'Agostino test. A probit plot was used to
confirm the bimodal distribution of the MR. 95% confi-
dence intervals were used and the level of statistical signif-
icance was set at p  < 0.05. Statistical analysis was
conducted using SPSS 10.0 for Windows (SPSS, USA) and
the GraphPad Prism 5.0 software (GraphPad Software Inc.
San Diego, Ca, USA).
Results
Allelic and genotypic frequencies for CYP2C19 were deter-
mined in 189 Colombian mestizos (51% men; age rank
18–56 years), data are shown in table 1. The frequency of
the native allele CYP2C19*1 was the highest (91.3%) fol-
lowed for the CYP2C19*2 allele (8.7%). The non func-
tional alleles *3, *4, *5, *6 and *8 were not detected.
Among the genotyped groups, 83.6% of the subjects were
homozygous for CYP2C19*1, 15.3% were heterozygous
for CYP2C19*1 (*1/*2) with one functional allele, and
1.1% of the subjects were homozygous for the non func-
tional allele CYP2C19*2 (*2/*2). Thus, the frequencies of
EMs, IMs and PMs were 83.6%, 15.3% and 1.1% respec-
tively. The distribution of genotypes for CYP2C19 were in
Hardy-Weinberg equilibrium (Chi = 0.26; df = 2; P =
0.88).
The averages of MR [log (omeprazole/hydroxyomepra-
zole)] for the three genotypes are statistically different
(table 2). The figure 1 shows the frequency distribution
histogram of the MR for the 44 phenotyped individuals.
The D'Agostino test indicated that the data deviated from
a normal distribution. The Probit analysis confirmed a
bimodal distribution with an antimode of 0.63 (figure 2).
For the individuals previously genotyped as EMs/IMs (n =
42), the values of log (omeprazole/hydroxyomeprazole)
were in the rank from -0.38 to 0.34, whereas those geno-
typed as PM (n = 2) were in the rank from 0.738 to 1.24,
showing a complete genotype-phenotype concordance
between the EMs/IMs and PMs.
Discussion and conclusion
Genetic polymorphisms are the more influential factors
for individual and interethnic variations in drug responses
[31]. The metabolic activity of CYP2C19 is genetically
controlled and individuals can be characterized as EMs,
IMs or PMs.
This is the first study evaluating the genotype and pheno-
type status of CYP2C19 in Colombian mestizos. The
CYP2C19 genetic profile found in this population, with
the *2 allele responsible for most of the deficient metab-
olizers, and the absence of *3, *4, *5, *6 and *8 variants,
is similar to Mexican-Americans profile [32], however, the
PMs frequency is lower (1,1% vs. 3,2%). Also, the fre-
quency of PMs found in our study is lower that the ones
reported in Caucasians (5%) [33], Blacks (5.4%) [10] and
Table 1: Allelic and genotypic frequencies of CYP2C19 in 
Colombian Mestizo individuals (n = 189). CI: confidence interval.
CYP2C19 
Alleles
Number of alleles Frequency (%) (95% CI)
*1 345 91.3 (88.5–94.1)








Number of subjects Frequency (%) (95% CI)
*1/*1 158 83.6 (78.3–88.9)
*1/*2 29 15.3 (10.2–20.4)
*2/*2 2 1.1 (0.4–3)BMC Clinical Pharmacology 2007, 7:6 http://www.biomedcentral.com/1472-6904/7/6
Page 4 of 5
(page number not for citation purposes)
West Mexicans [22], which are genetically related to Amer-
ican mestizos [5,6]. Since Amerindians are also part of the
American mestizo ancestor, it is interesting to mention
that PMs were not found in Cuna Amerindians of Panama
[34], whereas in Bolivian mestizos (an admixture between
white and Amerindian populations), the prevalence of
PMs is 1% [35].
The pharmacogenetic characterization becomes one of the
therapeutic options more cost-effective [36], because it is
helpful for both to prevent adverse drug reactions as well
as to enhance therapeutic efficiency in the case of drugs
with narrow therapeutic index. The genotype-phenotype
correlation found in this study, allows us to state that gen-
otyping only the *2 allele would have a high predictive
value of the CYP2C19 phenotype between Colombian
mestizos. Since pharmacogenetic allows the introduction
of personalized pharmacotherapy, according to individ-
ual genetic data, the results of this study will be useful for
drug dosage recommendations in Colombian mestizos.
For  CYP2C19  genotyping we used the minisequencing
Multiplex SnaPshot technique [26], which could be a safer
and more cost-effective strategy than the conventional
genotyping techniques based on allele-specific PCR or
RFLP (restriction fragment length polymorphism).
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Probit plot obtained by curve fitting of the log MR data from  44 healthy volunteers Figure 2
Probit plot obtained by curve fitting of the log MR data from 
44 healthy volunteers. The analysis revealed bimodality with 
the intersecting point at X = 0.63.
Table 2: Correlation between CYP2C19 genotype and MR in 
Colombian Mestizo individuals (n = 44). MR: Metabolic ratio, n: 
number of subjects, SD standard deviation.
GENOTYPE n MR (mean ± SD) P
*1/*1 39 -0.01 ± 0.15
*1/*2 3 0.23 ± 0.15
*2/*2 2 0.99 ± 0.35 <0.01
Frequency distribution of the hydroxylation indexes of Ome- prazole in Colombian mestizos Figure 1
Frequency distribution of the hydroxylation indexes of Ome-
prazole in Colombian mestizos. The arrow shows the anti-
mode (0.63). Individuals with an MR ≥ 0.63 were phenotyped 
as PMs.BMC Clinical Pharmacology 2007, 7:6 http://www.biomedcentral.com/1472-6904/7/6
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